Running Point Capital Advisors, LLC - INTERCEPT PHARMACEUTICALS IN ownership

INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 160 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2022. The put-call ratio across all filers is 0.59 and the average weighting 0.0%.

Quarter-by-quarter ownership
Running Point Capital Advisors, LLC ownership history of INTERCEPT PHARMACEUTICALS IN
ValueSharesWeighting
Q4 2022$123,700
-11.6%
10,0000.0%0.08%
-18.3%
Q3 2022$140,000
+1.4%
10,0000.0%0.09%
+4.5%
Q2 2022$138,000
-15.3%
10,000
-0.1%
0.09%
-6.3%
Q1 2022$163,00010,0110.10%
Other shareholders
INTERCEPT PHARMACEUTICALS IN shareholders Q3 2022
NameSharesValueWeighting ↓
Samsara BioCapital, LLC 640,688$9,514,0001.49%
CM Management, LLC 45,000$668,0000.50%
EULAV Asset Management 660,000$9,801,0000.26%
DLD Asset Management, LP 225,200$3,346,0000.24%
Virtus ETF Advisers LLC 21,387$318,0000.14%
GSA CAPITAL PARTNERS LLP 79,145$1,175,0000.12%
Hennion & Walsh Asset Management, Inc. 136,720$2,030,0000.11%
ALTRINSIC GLOBAL ADVISORS LLC 168,800$2,507,0000.08%
Inspire Investing, LLC 31,868$473,0000.06%
DUALITY ADVISERS, LP 51,196$760,0000.06%
View complete list of INTERCEPT PHARMACEUTICALS IN shareholders